Market Research Report
Biosimilar Insulin Market Access
|Published by||Datamonitor Healthcare||Product code||498961|
|Published||Content info||19 Pages
Delivery time: 1-2 business days
|Biosimilar Insulin Market Access|
|Published: January 26, 2018||Content info: 19 Pages||
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba. More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations. As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.